Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 5 (February 10), 2008: pp. 778-785
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.0235

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Publisher's Note
Right arrow Erratum (v26,p2793)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rastogi, P.
Right arrow Articles by Wolmark, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rastogi, P.
Right arrow Articles by Wolmark, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Priya Rastogi, Stewart J. Anderson, Harry D. Bear, Charles E. Geyer, Morton S. Kahlenberg, André Robidoux, Richard G. Margolese, James L. Hoehn, Victor G. Vogel, Shaker R. Dakhil, Deimante Tamkus, Karen M. King, Eduardo R. Pajon, Mary Johanna Wright, Jean Robert, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark

From the National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center; University of Pittsburgh Cancer Institute/Magee Womens Hospital; Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health; Allegheny General Hospital, Pittsburgh, PA; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of Texas Health Science Center at San Antonio, San Antonio, TX; Community Clinical Oncology Program Marshfield Clinic, Marshfield, WI; Cancer Center of Kansas, Wichita, KS; Division of Hematology/Oncology, Department of Medicine, Michigan State University College of Human Medicine, East Lansing, MI; Colorado Cancer Research Program, Denver, CO; Tulane University Health Sciences Center, New Orleans, LA; Cancer Center, Aultman Hospital Health Foundation, and Department of Surgery, Northeastern Ohio Universities College of Medicine, Canton, OH; Centre Hospitalier de l'Université de Montréal; Jewish General Hospital, McGill University, Montréal, Centre Hospitalier Affilié Universitaire de Québec (CHA)-Hôpital du Saint-Sacrement, Québec, Québec; Cross Cancer Institute, Edmonton, Alberta, Canada

Corresponding author: Priya Rastogi, MD, University of Pittsburgh Cancer Institute/Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213; e-mail: rastogip{at}upmc.edu

Purpose National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and overall survival (OS) compared with AC administered postoperatively. Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS.

Patients and Methods Analyses were limited to eligible patients. In B-18, 751 patients were assigned to receive preoperative AC, and 742 patients were assigned to receive postoperative AC. In B-27, 784 patients were assigned to receive preoperative AC followed by surgery, 783 patients were assigned to AC followed by T and surgery, and 777 patients were assigned to AC followed by surgery and then T.

Results Results from B-18 show no statistically significant differences in DFS and OS between the two groups. However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less than 50 years old (hazard ratio [HR] = 0.85, P = .09 for DFS; HR = 0.81, P = .06 for OS). DFS conditional on being event free for 5 years also demonstrated a strong trend in favor of the preoperative group (HR = 0.81, P = .053). Protocol B-27 results demonstrated that the addition of T to AC did not significantly impact DFS or OS. Preoperative T added to AC significantly increased the proportion of patients having pathologic complete responses (pCRs) compared with preoperative AC alone (26% v 13%, respectively; P < .0001). In both studies, patients who achieved a pCR continue to have significantly superior DFS and OS outcomes compared with patients who did not.

Conclusion B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy. B-27 also showed that the addition of preoperative taxanes to AC improves response.

Supported in part by Public Health Service Grants No. U10CA-12027, U10CA-69974, U10CA-37377, and U10CA-69651 from the National Cancer Institute, Department of Health and Human Services, and by AstraZeneca and sanofi-aventis.

Presented in part at the Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions, meeting hosted by the National Cancer Institute, March 26-27, 2007, Bethesda, MD.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
H. Jinno, M. Sakata, T. Hayashida, M. Takahashi, M. Mukai, T. Ikeda, and Y. Kitagawa
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
Ann. Onc., October 23, 2009; (2009) mdp428v1.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. Morrow, R. Jagsi, A. K. Alderman, J. J. Griggs, S. T. Hawley, A. S. Hamilton, J. J. Graff, and S. J. Katz
Surgeon Recommendations and Receipt of Mastectomy for Treatment of Breast Cancer
JAMA, October 14, 2009; 302(14): 1551 - 1556.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Frasci, G. D'Aiuto, P. Comella, M. D'Aiuto, M. Di Bonito, P. Ruffolo, G. Iodice, A. Petrillo, S. Lastoria, P. Oliviero, et al.
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908
Ann. Onc., October 8, 2009; (2009) mdp356v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. M. Sikov, D. S. Dizon, R. Strenger, R. D. Legare, K. P. Theall, T. A. Graves, J. S. Gass, T. A. Kennedy, and M. A. Fenton
Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
J. Clin. Oncol., October 1, 2009; 27(28): 4693 - 4700.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Jiralerspong, S. L. Palla, S. H. Giordano, F. Meric-Bernstam, C. Liedtke, C. M. Barnett, L. Hsu, M.-C. Hung, G. N. Hortobagyi, and A. M. Gonzalez-Angulo
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
J. Clin. Oncol., July 10, 2009; 27(20): 3297 - 3302.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
H.-M. Baek, J.-H. Chen, K. Nie, H. J. Yu, S. Bahri, R. S. Mehta, O. Nalcioglu, and M.-Y. Su
Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative 1H MR Spectroscopy
Radiology, June 1, 2009; 251(3): 653 - 662.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Gianni, J. Baselga, W. Eiermann, V. G. Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. L. Cussac, et al.
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
J. Clin. Oncol., May 20, 2009; 27(15): 2474 - 2481.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
H.-G. Moon, W. Han, J. W. Lee, E. Ko, E.-K. Kim, J.-H. Yu, S. Y. Kang, W. K. Moon, N. Cho, I.-A. Park, et al.
Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment
Ann. Onc., April 1, 2009; 20(4): 636 - 641.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Dumitra, L. Sideris, Y. Leclerc, G. Leblanc, and P. Dube
Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy
Ann. Onc., April 1, 2009; 20(4): 795 - 796.
[Full Text] [PDF]


Home page
Ann OncolHome page
A. Anton, A. Ruiz, M. A. Segui, L. Calvo, M. Munoz, J. Lao, F. Sancho, and L. Fernandez
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
Ann. Onc., March 1, 2009; 20(3): 454 - 459.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. S. Jeruss and T. K. Woodruff
Preservation of Fertility in Patients with Cancer
N. Engl. J. Med., February 26, 2009; 360(9): 902 - 911.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-Y. Pierga, F.-C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. de Cremoux, R. Salmon, A. Vincent-Salomon, and M. Marty
Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
Clin. Cancer Res., November 1, 2008; 14(21): 7004 - 7010.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Oncologist, November 1, 2008; 13(11): 1137 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M.-L. W. Ah-See, A. Makris, N. J. Taylor, M. Harrison, P. I. Richman, R. J. Burcombe, J. J. Stirling, J. A. d'Arcy, D. J. Collins, M. R. Pittam, et al.
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Clin. Cancer Res., October 15, 2008; 14(20): 6580 - 6589.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. K. Litton, A. M. Gonzalez-Angulo, C. L. Warneke, A. U. Buzdar, S.-W. Kau, M. Bondy, S. Mahabir, G. N. Hortobagyi, and A. M. Brewster
Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast Cancer
J. Clin. Oncol., September 1, 2008; 26(25): 4072 - 4077.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. J. Esteva and G. N. Hortobagyi
Can Early Response Assessment Guide Neoadjuvant Chemotherapy in Early-Stage Breast Cancer?
J Natl Cancer Inst, April 16, 2008; 100(8): 521 - 523.
[Full Text] [PDF]


Home page
JCOHome page
J. R. Gralow, J. A. Zujewski, and E. Winer
Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions
J. Clin. Oncol., February 10, 2008; 26(5): 696 - 697.
[Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
M. J. C. Ellis
Neoadjuvant Therapy for Breast Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 55 - 57.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online